According to the Medicine Intelligence Data Investment Pattern Database, surgical equipment company Nuomei Xinchuang Medical Technology (Shanghai) Co., Ltd. (hereinafter referred to as Nuomei Xinchuang) recently announced that it has successfully completed a new round of strategic financing, with a total financing amount of over 300 million yuan. This round of financing is led by Qiming Venture Capital and co invested by Sunshine Ronghui Capital. Star Bridge Capital serves as the exclusive financial advisor.

It is reported that the funds raised in this round will provide important financial support for the market expansion and product research and development of Nuomei Xinchuang, further helping the company to continue leading the field of ear, nose, throat, and cranial spine surgical instruments.

It is worth mentioning that according to the Medicine Intelligence Data Investment Pattern Database, this financing is the first financing for Novo Medical after its official name change. Its predecessor, Leno Medical, had previously completed six rounds of financing.

In recent years, the incidence rate of ear, nose and throat diseases in China has increased year by year. According to relevant statistics, there are about 20 million new patients with ear, nose and throat diseases in China every year. With the increase of patients, the number of surgeries for ear, nose and throat diseases has also significantly increased, with an annual growth rate of over 30%. The ear, nose and throat disease market has become a huge blue ocean market.

Nuomei Xinchuang is a leading domestic medical device company dedicated to providing comprehensive diagnosis and treatment services for otolaryngology and craniospinal surgery, integrating research and development, production, and sales. Its predecessor was Leno Medical, established in 2015. Previously, Leno Medical has made multiple strategic mergers and acquisitions, rapidly expanding its product pipeline: In 2019, it merged with Chengdu Meichuang Medical, a leading medical plasma technology platform in China; In December 2021, Hangzhou Tonglusco Medical Equipment Co., Ltd., a leading domestic manufacturer of ear, nose, throat, and cranial spine surgical instruments, was acquired; In March 2022, fully acquired Endodoctor's high-end endoscopic system from Germany; In November 2022, Guizhou Zirui Technology Co., Ltd. officially joined Nuomei New Creation.

Through these mergers and acquisitions, Nuomei Xinchuang has successfully built a Chinese otolaryngology and craniospinal surgical instrument platform. According to the official website of Nuomei Xinchuang, its departmental solutions are mainly divided into four major areas, namely otolaryngology, orthopedics, urology&gynecology, and hepatobiliary fields.

At present, Novomi's core products include low-temperature plasma surgical systems, power systems, medical endoscopic camera systems, temperature controlled high-frequency surgical treatment devices, Eustachian tube balloon dilation catheters, sinus balloons, disposable nasopharyngeal airways, sinus drug-eluting stents, surgical instruments, etc. According to Nuomei Xinchuang, its main products have a market share of over 30% and have become a leading enterprise in otolaryngology and craniospinal surgery in China.

Among them, Nuomei Xinchuang has a globally innovative ear, nose and throat power system solution in the field of ear, nose and throat, with product performance surpassing imported brands. Its technology details such as low-temperature water cooling, detachable parts, maximum 160000 RPM, and eccentric shaft design are industry-leading, while reducing costs through integrated design, truly benefiting patients.

Nuomei Xinchuang has pioneered the Chinese TCA (Temperature Controlled Ablation) product, which is synchronized with international new technologies. This product uses nerve ablation technology to precisely destroy the posterior nasal nerve and its branches, effectively relieving symptoms of rhinitis. The surgery is performed under local anesthesia with the help of a sinus endoscope, allowing for daytime surgery. Since its launch, TCA products have gained high recognition from patients and brought good news to them due to their significant therapeutic effects.

In August 2024, Nuomei Xinchuang also made a new breakthrough in nose planing technology. The non clogging planing knife was officially launched. The product technology has undergone a certain leak prevention treatment at the soft spring that would have leaked water, ensuring that the internal water flow reaches the tooth end of the planing knife. Through a certain method, the internal water flow pressure increasing effect is created, increasing the tissue's pushing ability and lubrication during the cutting process, thereby achieving non clogging and more efficient use.

The proactive water injection boosting technology has broken through the drawbacks of traditional planer blades, where internal water leakage occurs at the bending of the planer blade and water injection cannot reach the tooth end. It can perform leak prevention treatment inside the bending of the planer blade, allowing water injection to reach the tooth end of the blade, actively providing internal pressurized water flow to the blade window, and timely pushing the excised tissue.

Source: https://news.yaozh.com/archive/45011.html